menu
The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%,
The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%,
The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030

The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030

Roots Analysis has done a detailed study on Antibody Discovery:Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.

 

To order this 450+ pagereport, which features 120+ figures and 140+ tables, please visit this link

 

Key Market Insights

§  Over 80 companies areoffering antibody discovery services; of these, more than 75 players claim tooffer services related to hit generation.

§  Nearly 180 innovativetechnology platforms have been developed by numerous firms for the purpose ofantibody discovery.

§  Majority ofstakeholders in the competitive market landscape are small / mid-sized firms,catering to the needs of a diverse clientele.

§  In order to get anedge over their competitors in the industry, companies have established theirpresence in different regions across the globe.

§  The rising interest in this field is reflected in the number ofpartnerships inked in the recent past, involving both international andindigenous stakeholders, and focused on antibody discovery for diverse range ofindications.

§  Efforts of theplayers in the field of antibody discovery have garnered significant interestof several venture capital investors.

§  The antibody discovery services market is expected to witness growth ata CAGR of ~10%; the anticipated opportunity is likely to be distributed acrossvarious steps involved in antibody discovery, antibody discovery method, natureof antibody generated and geographies.

§  The market forantibody discovery platforms is currently being driven by the revenues from thelicensing deals; it is anticipated to reach USD 5.9 billion by 2030.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

                                                                                                               

Table of Contents

 

1.         PREFACE

1.1.        Scope of the Report

1.2.        Research Methodology

1.3.        Chapter Outlines

 

2.         EXECUTIVESUMMARY

 

3.         INTRODUCTION

3.1.       ChapterOverview

3.2.       Structureof Antibodies

3.3.       History ofDevelopment

3.4.       AntibodyIsotypes

3.5.       Mechanismof Action of Antibodies

3.6.       Classificationof Antibodies

3.6.1.    MonoclonalAntibodies

3.6.2.    Polyclonal Antibodies

3.6.3.    BispecificAntibodies

3.7.       Applicationsof Antibodies

 

 

 

PressRelease: Variation 2 (Format 3)

 

4.         ANTIBODYDISCOVERY PROCESS AND METHODS

4.1.       ChapterOverview

4.2.       AntibodyDiscovery Process

4.2.1.    TargetSelection and Validation

4.2.2.    HitGeneration

4.2.3.    LeadSelection

4.2.4.    LeadOptimization

4.2.4.1. Humanization

4.2.4.2. AffinityMaturation

4.2.4.3. FcEngineering

4.2.5.    LeadCharacterization

4.2.6.    CandidateSelection

 

4.3.       AntibodyDiscovery Methods

4.3.1.    HybridomaMethod

4.3.2.    In vitroDisplay Method

4.3.2.1. PhageDisplay

4.3.2.2. YeastDisplay

4.3.2.3. RibosomalDisplay

4.3.3.    TransgenicAnimal-Based Method

4.3.4.    Single BCell-Based Method

4.3.5.    Advantagesand Disadvantages of Existing Antibody Discovery Techniques

 

4.4.       Evolutionof Monoclonal Antibodies

4.4.1.    Fully HumanMonoclonal Antibodies

 

5.         ANTIBODYDISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

5.1.       ChapterOverview

5.2.       AntibodyDiscovery Service Providers: List of Industry Players

5.2.1.    Analysis byYear of Establishment

5.2.2.    Analysis byCompany Size

5.2.3.    Analysis byLocation of Headquarters

5.2.4.    Analysis byType of Service Offered

5.2.5.    Analysis byType of Antibody Discovery Method

5.2.6.    GridRepresentation: Analysis by Type of Service Offered, Type of Antibody DiscoveryMethod and Company Size

5.2.7.    Analysis byAnimal Model Used

5.2.8.    Analysis byType of Antibody Discovered

5.2.9.    Analysis byType of Antibody Discovery Method and Type of Antibody Discovered

5.2.10.  Analysis byPurpose of Antibody Discovery

5.2.11.  Analysis byType of Antibody Discovery Method and Purpose of Antibody Discovery

 

6.         COMPANYCOMPETITIVENESS ANALYSIS

6.1.       ChapterOverview

6.2.       Methodology

6.3.       KeyParameters

6.4.       Competitiveness Analysis: Antibody Discovery Service Providers

6.4.1.    AntibodyDiscovery Service Providers based in North America

6.4.2.    AntibodyDiscovery Service Providers based in Europe

6.4.3.    AntibodyDiscovery Service Providers based in Asia Pacific

 

7.         COMPANYPROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

7.1.       ChapterOverview

7.2.       AntibodyDiscovery Service Providers in North America

7.2.1.    Abwiz Bio

7.2.1.1. CompanyOverview

PressRelease: Variation 2 (Format 3)

 

7.2.1.2. AntibodyDiscovery Services

7.2.1.3. RecentDevelopments and Future Outlook

 

7.2.2.    AragenBioscience (A GVK BIO Company)

7.2.2.1. CompanyOverview

7.2.2.2. AntibodyDiscovery Services

7.2.2.3. RecentDevelopments and Future Outlook

 

7.2.3.    DistributedBio

7.2.3.1. CompanyOverview

7.2.3.2. AntibodyDiscovery Services

7.2.3.3. RecentDevelopments and Future Outlook

 

7.2.4.    IntegralMolecular

7.2.4.1. CompanyOverview

7.2.4.2. Antibody DiscoveryServices

7.2.4.3. RecentDevelopments and Future Outlook

 

7.2.5.    LakePharma

7.2.5.1. CompanyOverview

7.2.5.2. AntibodyDiscovery Services

7.2.5.3. RecentDevelopments and Future Outlook

 

7.3.       AntibodyDiscovery Service Providers in Europe

7.3.1.    Abzena

7.3.1.1. CompanyOverview

7.3.1.2. FinancialInformation

7.3.1.3. AntibodyDiscovery Services

7.3.1.4. RecentDevelopments and Future Outlook

 

7.3.2.    ImmunoPrecise Antibodies

7.3.2.1. CompanyOverview

7.3.2.2. FinancialInformation

7.3.2.3. AntibodyDiscovery Services

7.3.2.4. RecentDevelopments and Future Outlook

 

7.3.3.    PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)

7.3.3.1. CompanyOverview

7.3.3.2. AntibodyDiscovery Services

7.3.3.3. RecentDevelopments and Future Outlook

 

7.4.       AntibodyDiscovery Service Providers in Asia-Pacific

7.4.1.    ChemPartner

7.4.1.1. CompanyOverview

7.4.1.2. AntibodyDiscovery Services

7.4.1.3. RecentDevelopments and Future Outlook

 

7.4.2.    VivaBiotech

7.4.2.1. CompanyOverview

7.4.2.2. FinancialInformation

7.4.2.3. AntibodyDiscovery Services

7.4.2.4. RecentDevelopments and Future Outlook

 

7.4.3.    WuXiBiologics

7.4.3.1. CompanyOverview

7.4.3.2. FinancialInformation

PressRelease: Variation 2 (Format 3)

 

7.4.3.3. AntibodyDiscovery Services

7.4.3.4. RecentDevelopments and Future Outlook

 

8.         ANTIBODYDISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE

8.1.       ChapterOverview

8.2.       AntibodyDiscovery Platform Providers: List of Industry Players

8.2.1.    Analysis byYear of Establishment

8.2.2.    Analysis byCompany Size

8.2.3.    Analysis byLocation of Headquarters

8.2.4.    Analysis byType of Antibody Discovered

8.3.       AntibodyDiscovery: List of Technologies and Platforms

8.3.1.    Analysis byType of Antibody Discovery Method

8.3.2.    Analysis byType of Antibody Discovery Method and Location of Headquarters

8.3.3.    Analysis byAnimal Model Used

8.3.4.    Analysis byPatent Availability

 

9.         TECHNOLOGYCOMPETITIVENESS ANALYSIS

9.1.       ChapterOverview

9.2.       Methodology

9.3.       KeyParameters

9.4.       TechnologyCompetitiveness Analysis: Antibody Discovery Platforms

9.4.1.    Competitiveness Analysis: Library Based Antibody Discovery Platforms

9.4.2.    Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms

9.4.3.    Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms

9.4.4.    Competitiveness Analysis: Other Antibody Discovery Platforms

 

10.        COMPANYPROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

10.1.     ChapterOverview

10.2.     ImmunoPrecise Antibodies

10.2.1.  CompanyOverview

10.2.2.  FinancialInformation

10.2.3.  Portfolio ofAntibody Discovery Platforms

10.2.3.1. Abthena™

10.2.3.2. B cell Select™

10.2.3.3. DeepDisplay™

10.2.3.4. ModiFuse™

10.2.3.5. ModiPhage™

10.2.3.6. ModiSelect™

10.2.3.7. ModiTune™

10.2.4.   Recent Developments and Future Outlook

 

10.3.     HarbourBioMed

10.3.1.  CompanyOverview

10.3.2.  Portfolio ofAntibody Discovery Platforms

10.3.2.1. H2L2 Platform

10.3.2.2. HCAb Platform

10.3.3.   Recent Developments and Future Outlook

 

10.4.     Kymab

10.4.1.  CompanyOverview

10.4.2.  Portfolio ofAntibody Discovery Platforms

10.4.2.1. Kymouse™

10.4.2.2. IntelliSelect®

10.4.3.   Recent Developments and Future Outlook

 

10.5.     LigandPharmaceuticals

PressRelease: Variation 2 (Format 3)

 

10.5.1.  CompanyOverview

10.5.2.  FinancialInformation

10.5.3.  Portfolio ofAntibody Discovery Platforms

10.5.3.1. OmniAb®

10.5.3.1.1. OmniChicken®

10.5.3.1.2. OmniClic™

10.5.3.1.3. OmniFlic®

10.5.3.1.4. OmniMouse®

10.5.3.1.5. OmniRat®

10.5.4.  Recent Developmentsand Future Outlook

 

10.6.     MorphoSys

10.6.1.  CompanyOverview

10.6.2.  FinancialInformation

10.6.3.  Portfolio ofAntibody Discovery Platforms

10.6.3.1. arYla® Technology

10.6.3.2. HuCAL® Technology

10.6.3.3. Ylanthia® Technology

10.6.4.  RecentDevelopments and Future Outlook

 

11.        REGIONALCAPABILITY ANALYSIS

11.1.     ChapterOverview

11.2.     KeyAssumptions and Methodology

11.3.     RegionalCapability Analysis: Antibody Discovery Service Providers

11.3.1.  RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin North America

11.3.2.  RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin Europe

11.3.3.  RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin Asia-Pacific

 

11.4.     RegionalCapability Analysis: Antibody Discovery Platform Providers

11.4.1.  RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in North America

11.4.2.  RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in Europe

11.4.3.  RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in Asia-Pacific

 

11.5.     ConcludingRemarks

 

12.        PARTNERSHIPSAND COLLABORATIONS

12.1.     ChapterOverview

12.2.     PartnershipModels

12.3.     List ofPartnerships and Collaborations

12.3.1.  Analysis byYear of Partnership

12.3.2.  Analysis byType of Partnership

12.3.3.  Analysis bythe Type of Company (Service / Platform Providers)

12.3.4.  Analysis byType of Antibody Discovered

12.3.5.  Analysis byYear of Partnership and Type of Partner

12.3.6.  Analysis byType of Partnership and Type of Partner

12.3.7.  Most ActivePlayers: Analysis by Number of Partnerships

12.3.8.  Most PopularTechnologies: Analysis by Number of Partnerships

12.3.9.  RegionalAnalysis

12.3.9.1. Intercontinental and Intracontinental Agreements

 

PressRelease: Variation 2 (Format 3)

 

13.        FUNDINGAND INVESTMENT ANALYSIS

13.1.     ChapterOverview

13.2.     Types ofFunding

13.3.     AntibodyDiscovery Service and Platform Providers: Funding and Investment Analysis

13.3.1.  Analysis byNumber of Instances

13.3.2.  Analysis byAmount Invested

13.3.3.  Analysis byType of Funding

13.3.4.  Most ActivePlayers: Analysis by Amount Invested

13.3.5.  Most ActiveInvestors: Analysis by Number of Funding Instances

13.3.6.  RegionalAnalysis by Amount Invested

 

13.4.     ConcludingRemarks

 

14.        ANTIBODYDISCOVERY SERVICES: MARKET FORECAST

14.1.     ChapterOverview

14.2.     ForecastMethodology

14.3.     GlobalAntibody Discovery Services Market, 2020-2030

14.4.     GlobalAntibody Discovery Services Market: Distribution by Steps Involved in AntibodyDiscovery Process, 2020-2030

14.4.1.  AntibodyDiscovery Services Market for Antigen Designing, 2020-2030

14.4.2.  AntibodyDiscovery Services Market for Hit Generation, 2020-2030

14.4.3.  AntibodyDiscovery Services Market for Lead Selection, 2020-2030

14.4.4.  AntibodyDiscovery Services Market for Lead Optimization, 2020-2030

14.4.5.  AntibodyDiscovery Services Market for Lead Characterization, 2020-2030

14.5.     GlobalAntibody Discovery Services Market: Distribution by Antibody Discovery Method,2020-2030

14.5.1.  AntibodyDiscovery Services Market for Phage Display, 2020-2030

14.5.2.  AntibodyDiscovery Services Market for Yeast Display, 2020-2030

14.5.3.  Antibody DiscoveryServices Market for Hybridoma Method, 2020-2030

14.5.4.  AntibodyDiscovery Services Market for Transgenic Animal Based Method, 2020-2030

14.5.5.  AntibodyDiscovery Services Market for Single Cell Based Method, 2020-2030

14.5.6.  AntibodyDiscovery Services Market for Other Methods, 2020-2030

14.6.     GlobalAntibody Discovery Services Market: Distribution by Nature of AntibodyGenerated, 2020-2030

14.6.1.  AntibodyDiscovery Services Market for Humanized Antibodies, 2020-2030

14.6.2.  AntibodyDiscovery Services Market for Human Antibodies, 2020-2030

14.6.3.  AntibodyDiscovery Services Market for Chimeric Antibodies, 2020-2030

14.6.4.  AntibodyDiscovery Services Market for Murine Antibodies, 2020-2030

14.7.     GlobalAntibody Discovery Services Market: Distribution by Region, 2020-2030

14.7.1.  AntibodyDiscovery Services Market in North America, 2020-2030

14.7.2.  AntibodyDiscovery Services Market in Europe, 2020-2030

14.7.3.  AntibodyDiscovery Services Market in Asia-Pacific and Rest of the World, 2020-2030

14.7.4.  AntibodyDiscovery Services: Market Attractiveness Analysis by Region

 

15.        ANTIBODYDISCOVERY TECHNOLOGIES: MARKET FORECAST

15.1.     ChapterOverview

15.2.     KeyAssumptions

15.3.     ForecastMethodology

15.4.     GlobalAntibody Discovery Platforms Market, 2020-2030

15.5.     GlobalAntibody Discovery Platforms Market: Distribution by Region, 2020-2030

15.5.1.  AntibodyDiscovery Platforms Market in North America, 2020-2030

15.5.2.  AntibodyDiscovery Platforms Market in Europe, 2020-2030

15.5.3.  AntibodyDiscovery Platforms Market in Asia-Pacific, 2020-2030

 

16.        CASE INPOINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

16.1.     ChapterOverview

PressRelease: Variation 2 (Format 3)

 

16.2.     Humira®(Adalimumab)

16.2.1.  DrugOverview

16.2.2.  DiscoveryProcess and Method

16.2.3.  HistoricalSales

 

16.3.     Keytruda®(Pembrolizumab)

16.3.1.  DrugOverview

16.3.2.  DiscoveryProcess and Method

16.3.3.  HistoricalSales

 

16.4.     Herceptin®(Trastuzumab)

16.4.1.  DrugOverview

16.4.2.  DiscoveryProcess and Method

16.4.3.  HistoricalSales

 

16.5.     Avastin®(Bevacizumab)

16.5.1.  DrugOverview

16.5.2.  DiscoveryProcess and Method

16.5.3.  HistoricalSales

 

16.6.     Rituxan®(Rituximab)

16.6.1.  DrugOverview

16.6.2.  DiscoveryProcess and Method

16.6.3.  HistoricalSales

 

17.        CASESTUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION

17.1.     Importanceof Antibody Humanization and Affinity Maturation

17.2.     AntibodyHumanization and Affinity Maturation Service and Platform Providers: MarketLandscape

17.3.     AntibodyHumanization: Publication Analysis

17.3.1.  PublicationAnalysis: Year-Wise Trend

17.3.2.  PublicationAnalysis: Key Journals

17.3.3.  PublicationAnalysis: Distribution by Animal Model Used

17.3.4.  PublicationAnalysis: Distribution by Method Used for Humanization

17.4.     AntibodyHumanization Service and Platform Providers: SWOT Analysis

 

18.        FUTUREGROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

18.1.     ChapterOverview

18.2.     AnticipatedShift from Monoclonal Antibodies to Other Novel Formats

18.3.     Technological Advancements to Overhaul Conventional Antibody DiscoveryProcesses

18.4.     Transitionto CADD-based Approaches to Help Achieve Better Operational Efficiencies

18.5.     RisingDemand for Antibody-based Treatment Options across Non-Oncology Indications

18.6.     GrowingMarket Opportunities in the Asia-Pacific Region

18.7.     ExpectedIncrease in Number of Collaborations and Licensing Activity

18.8.     ConcludingRemarks

 

19.        EXECUTIVEINSIGHTS

19.1.     ChapterOverview

 

19.2.     AbverisAntibody

19.2.1.  CompanySnapshot

19.2.2.  TraceyMullen, Chief Executive Officer (Q2 2020)

 

19.3.     NidusBiosciences

19.3.1.  CompanySnapshot

19.3.2.  LisaDelouise, Founder and Chief Technology Officer (Q1 2020)

PressRelease: Variation 2 (Format 3)

 

19.4.     AvantGen

19.4.1.  CompanySnapshot

19.4.2.  Mark Kubik,Chief Business Officer (Q1 2020)

 

19.5.     Single CellTechnology

19.5.1.  CompanySnapshot

19.5.2.  Chun-NanChen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

 

19.6.     DistributedBio

19.6.1.  CompanySnapshot

19.6.2.  Giles Day,Co-Founder and Chief Executive Officer (Q2 2018)

 

19.7.     AbCellera

19.7.1.  CompanySnapshot

19.7.2.  KevinHeyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

 

19.8.     AbGenicsLife Sciences

19.8.1.  CompanySnapshot

19.8.2.  Sanjiban KBanerjee, Director (Q2 2018)

 

19.9.     CDILaboratories

19.9.1.  CompanySnapshot

19.9.2.  IgnacioPino, Chief Executive Officer and President (Q2 2017)

 

19.10.   APBiosciences

19.10.1. Company Snapshot

19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

 

19.11.   YUMAB

19.11.1. Company Snapshot

19.11.2. Thomas Schirrmann, Chief Executive Officer and GeneralManager (Q2 2017)

 

19.12.   AntibodySolutions

19.12.1. Company Snapshot

19.12.2. Debra Valsamis, Business Development Associate (Q22017)

 

19.13.   LigandPharmaceuticals

19.13.1. Company Snapshot

19.13.2. Christel Iffland, Vice President (Q2 2017)

 

19.14.   LakePharma

19.14.1. Company Snapshot

19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

 

20.        CONCLUDINGREMARKS

20.1.     ChapterOverview

20.2.     KeyTakeaways

 

21.        APPENDIX1: TABULATED DATA

 

22.        APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com